Cytokinetics (CYTK) Total Debt (2010 - 2026)

Cytokinetics (CYTK) has reported Total Debt for 15 consecutive years, with $292.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Debt rose 178.15% year-over-year to $292.0 million; the TTM figure through Mar 2026 stood at $292.0 million (up 178.15% YoY), while the FY2025 annual figure was $287.6 million, up 174.53% from the prior year.
• Total Debt climbed to $292.0 million in Q1 2026 per CYTK's latest filing, from $287.6 million in the prior quarter.
• Across five years, Total Debt topped out at $292.0 million in Q1 2026 and bottomed at $60.9 million in Q3 2023.
• Historically, Total Debt has averaged $113.2 million across 5 years, with a median of $68.5 million in 2023.
• Annual changes were most pronounced in 2023 — Total Debt declined 4.18% — and 2026, when it jumped 178.15%.
• Cytokinetics' Total Debt stood at $64.8 million in 2022, then gained by 5.71% to $68.5 million in 2023, then surged by 53.0% to $104.7 million in 2024, then soared by 174.53% to $287.6 million in 2025, then increased by 1.55% to $292.0 million in 2026.
• Business Quant data shows CYTK's Total Debt at $292.0 million in Q1 2026, $287.6 million in Q4 2025, and $176.0 million in Q3 2025.